Search Results - "Dörken, B"

Notch is an essential upstream regulator of NF-κB and is relevant for survival of Hodgkin and Reed-Sternberg cells by Schwarzer, R, Dörken, B, Jundt, F

“…A major pathogenetic mechanism in classical Hodgkin lymphoma (cHL) is constitutive activation of canonical nuclear factor-κB (NF-κB) p50/p65 signaling,…”
Get full text

Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes by Pfeifer, M, Zheng, B, Erdmann, T, Koeppen, H, McCord, R, Grau, M, Staiger, A, Chai, A, Sandmann, T, Madle, H, Dörken, B, Chu, Y-W, Chen, A I, Lebovic, D, Salles, G A, Czuczman, M S, Palanca-Wessels, M C, Press, O W, Advani, R, Morschhauser, F, Cheson, B D, Lenz, P, Ott, G, Polson, A G, Mundt, K E, Lenz, G

“…Antibody drug conjugates (ADCs), in which cytotoxic drugs are linked to antibodies targeting antigens on tumor cells, represent promising novel agents for the…”
Get full text

Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma by Wurster, K D, Hummel, F, Richter, J, Giefing, M, Hartmann, S, Hansmann, M-L, Kreher, S, Köchert, K, Krappmann, D, Klapper, W, Hummel, M, Wenzel, S-S, Lenz, G, Janz, M, Dörken, B, Siebert, R, Mathas, S

“…Apart from its unique histopathological appearance with rare tumor cells embedded in an inflammatory background of bystander cells, classical Hodgkin lymphoma…”
Get full text

α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study by Sinn, M, Denkert, C, Striefler, J K, Pelzer, U, Stieler, J M, Bahra, M, Lohneis, P, Dörken, B, Oettle, H, Riess, H, Sinn, B V

“…Background: Previous investigations in pancreatic cancer suggest a prognostic role for α -smooth muscle actin ( α -SMA) expression and stromal density in the…”
Get full text

Serum glucocorticoid-regulated kinase 1 ( ) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells by Fagerli, U-M, Ullrich, K, Stühmer, T, Holien, T, Köchert, K, Holt, R U, Bruland, O, Chatterjee, M, Nogai, H, Lenz, G, Shaughnessy, J D, Mathas, S, Sundan, A, Bargou, R C, Dörken, B, Børset, M, Janz, M

“…Multiple myeloma (MM) is a paradigm for a malignant disease that exploits external stimuli of the microenvironment for growth and survival. A thorough…”
Get full text

Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma by Meyer, A.H., Stroux, A., Lerch, K., Eucker, J., Eitle, J., Hohloch, K., Andrzejak, M., Possinger, K., Dörken, B., Pezzutto, A., Scholz, C.W.

“…Marginal zone lymphoma (MZL) is a non-Hodgkin lymphoma that occurs as extra nodal, nodal, or splenic. While MZL is generally considered an indolent disease, a…”
Get full text

High-level expression of Mastermind-like 2 contributes to aberrant activation of the NOTCH signaling pathway in human lymphomas by Köchert, K, Ullrich, K, Kreher, S, Aster, J C, Kitagawa, M, Jöhrens, K, Anagnostopoulos, I, Jundt, F, Lamprecht, B, Zimber-Strobl, U, Stein, H, Janz, M, Dörken, B, Mathas, S

“…Inappropriate activation of the NOTCH signaling pathway, for example, by activating mutations, contributes to the pathogenesis of various human malignancies…”
Get full text

Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease by Josting, A., Rudolph, C., Reiser, M., Mapara, M., Sieber, M., Kirchner, H. H., Dörken, B., Hossfeld, D. K., Diehl, V., Engert, A.

“…Background: An important variable affecting outcome in relapsed and refractory Hodgkin’s disease (HD) is the potential of conventional salvage chemotherapy to…”
Get full text

SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study by Sinn, M., Sinn, B.V., Striefler, J.K., Lindner, J.L., Stieler, J.M., Lohneis, P., Bischoff, S., Bläker, H., Pelzer, U., Bahra, M., Dietel, M., Dörken, B., Oettle, H., Riess, H., Denkert, C.

“…Previous investigations in pancreatic cancer suggested a prognostic role for secreted protein acidic and rich in cysteine (SPARC) expression in the peritumoral…”
Get full text

Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG) by Josting, A., Rudolph, C., Mapara, M., Glossmann, J.-P., Sienawski, M., Sieber, M., Kirchner, H. H., Dörken, B., Hossfeld, D. K., Kisro, J., Metzner, B., Berdel, W. E., Diehl, V., Engert, A.

“…Background: We designed a dose- and time-intensified high-dose sequential chemotherapy regimen for patients with relapsed and refractory Hodgkin lymphoma (HD)…”
Get full text

Cellular senescence predicts treatment outcome in metastasised colorectal cancer by Haugstetter, A M, Loddenkemper, C, Lenze, D, Gröne, J, Standfuß, C, Petersen, I, Dörken, B, Schmitt, C A

“…Background: Cellular senescence is a terminal cell-cycle arrest that occurs in response to activated oncogenes and DNA-damaging chemotherapy. Whether cancer…”
Get full text

The tumour suppressor p53 is frequently nonfunctional in Sézary syndrome by Lamprecht, B., Kreher, S., Möbs, M., Sterry, W., Dörken, B., Janz, M., Assaf, C., Mathas, S.

“…Summary Background  Primary cutaneous T‐cell lymphomas (CTCLs) are a heterogeneous group with Sézary syndrome (SS) as one of the most aggressive variants…”
Get full text

Antisense therapy in oncology: new hope for an old idea? by Tamm, Ingo, Dörken, Bernd, Hartmann, Gunther

“…There is a potential role for antisense oligonucleotides in the treatment of disease. The principle of antisense technology is the sequence-specific binding of…”
Get full text

PI3-K AKT FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells by Lentzsch, S, Chatterjee, M, Gries, M, Bommert, K, Gollasch, H, Dörken, B, Bargou, R C

“…IL-6 has been reported to play a central role in growth and survival of multiple myeloma (MM) cells. However, recently we have demonstrated that in the…”
Get full text

Effect of Anti‐CD 20 Antibody Rituximab in Patients with Post‐Transplant Lymphoproliferative Disorder (PTLD) by Oertel, Stephan H.K., Verschuuren, Erik, Reinke, Petra, Zeidler, Kristin, Papp‐Váry, Matthias, Babel, Nina, Trappe, Ralf U., Jonas, Sven, Hummel, Manfred, Anagnostopoulos, Ioannis, Dörken, Bernd, Riess, Hanno B.

“…Post‐transplant lymphoproliferative disorders (PTLD) are a life‐threatening complication following solid organ transplantation. Treatment with rituximab, a…”
Get full text

Long-term follow-up of fertility and pregnancy in autoimmune diseases after autologous haematopoietic stem cell transplantation by Massenkeil, G., Alexander, T., Rosen, O., Dörken, B., Burmester, G., Radbruch, A., Hiepe, F., Arnold, R.

“…Issues of fertility and pregnancy require special attention in the long-term care of patients with autoimmune diseases (AD), who are candidates for…”
Get full text

An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma by Hay, A.E., Klimm, B., Chen, B.E., Goergen, H., Shepherd, L.E., Fuchs, M., Gospodarowicz, M.K., Borchmann, P., Connors, J.M., Markova, J., Crump, M., Lohri, A., Winter, J.N., Dörken, B., Pearcey, R.G., Diehl, V., Horning, S.J., Eich, H.T., Engert, A., Meyer, R.M.

“…Treatment options for patients with nonbulky stage IA–IIA Hodgkin lymphoma include combined modality therapy (CMT) using doxorubicin, bleomycin, vinblastine…”
Get full text

NIH-defined graft-versus-host disease and evidence for a potent graft-versus-leukemia effect in patients with acute lymphoblastic leukemia by Terwey, T.H., Le Duc, T.M., Hemmati, P.G., le Coutre, P., Nagy, M., Martus, P., Dörken, B., Arnold, R.

“…The prognostic value of the NIH consensus criteria for graft-versus-host disease (GVHD) is not well defined yet. We analyzed NIH-defined GVHD in 147 acute…”
Get full text

Corrections to “SPARC expression in resected pancreatic cancer patients treated with Gemcitabine: results from the CONKO-001 study” by Sinn, M., Sinn, B.V., Striefler, J.K., Lindner, J.L., Stieler, J.M., Lohneis, P., Bischoff, S., Bläker, H., Pelzer, U., Bahra, M., Dietel, M., Dörken, B., Oettle, H., Riess, H., Denkert, C.

Get full text

Notch pathway inhibition controls myeloma bone disease in the murine MOPC315.BM model by Schwarzer, R, Nickel, N, Godau, J, Willie, B M, Duda, G N, Schwarzer, R, Cirovic, B, Leutz, A, Manz, R, Bogen, B, Dörken, B, Jundt, F

“…Despite evidence that deregulated Notch signalling is a master regulator of multiple myeloma (MM) pathogenesis, its contribution to myeloma bone disease…”
Get full text